New shot could replace IV drips for rare muscle disease

NCT ID NCT05514873

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tested whether people with generalized myasthenia gravis could safely switch from intravenous (IV) infusions of complement inhibitors to daily injections of zilucoplan. Twenty-six participants who were stable on IV therapy switched to the subcutaneous shot. The main focus was on safety and tolerability, with secondary measures of symptom control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zilucoplan
What this could lead to: If successful, this could offer a more convenient at-home injection option for people with generalized myasthenia gravis who currently need regular IV infusions.
What could go wrong: This is a small, single-arm study (26 people) with no comparison group, so results may not apply broadly. The main goal is safety, not proof of superior effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Locations

Mg0017 50076

Columbus, Ohio, 43221, United States
Mg0017 50086

Charlotte, North Carolina, 28207, United States
Mg0017 50099

San Francisco, California, 94143, United States
Mg0017 50111

Seattle, Washington, 98195-0001, United States
Mg0017 50304

Dallas, Texas, 75390-8866, United States
Mg0017 50555

Austin, Texas, 78759, United States
Mg0017 50556

Chapel Hill, North Carolina, 27599, United States
Mg0017 50557

O'Fallon, Illinois, 62269, United States
Mg0017 50559

Los Angeles, California, 90095, United States
Mg0017 50564

Scottsdale, Arizona, 85251, United States
Mg0017 50569

Greenfield, Wisconsin, 53228, United States
Mg0017 50593

Rancho Mirage, California, 92270, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.